Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| Mutant EGFR inhibitor | Mutant EGFR inhibitor is a potent and selective mutant EGFR inhibitor extracted from patent WO 2013014448 A1. It inhibits EGFRL858R, EGFRExon 19 deletionand EGFRT790M. Group: Pharmaceutical. Alternative Names: MDK3627; MDK 3627; MDK-3627; Mutant EGFR inhibitor. CAS No. 1421373-62-7. Pack Sizes: 5 mg. Product ID: B0084-463231. Molecular formula: C27H30ClN7O2. Mole weight: 520.03. Custom synthesis is available. Send your inquiries for more information. |  London |
| AZD3759 | AZD3759 is a n orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3759 binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. Group: Pharmaceutical. Alternative Names: AZD3759; AZD-3759; AZD 3759. CAS No. 1626387-80-1. Pack Sizes: 1 g. Product ID: B0084-470884. Molecular formula: C22H23ClFN5O3. Mole weight: 459.91. Custom synthesis is available. Send your inquiries for more information. | London |
| Brigatinib | Brigatinib, also known as AP-26113, is an orally active, potent and selective dual ALK/EGFR inhibitor. AP26113 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK; IC50 < 100 nM in Ba/F3 cells). AP26113 binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. It blocks ALK activity and reduces growth in neuroblastoma cells, mouse xenograft, and Drosophila model systems harboring constitutively active ALK variants. Group: Pharmaceutical. Alternative Names: AP26113. CAS No. 1197953-54-0. Pack Sizes: 1 g. Product ID: B0084-470820. Molecular formula: C29H39ClN7O2P. Mole weight: 584.1. Custom synthesis is available. Send your inquiries for more information. | London |
| CNX-2006 | CNX-2006 is a potent and mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbouring the T790M mutation. CNX-2006 is the prototype for CO-1686, which is currently in a Phase I clinical trial for the treatment of EGFR-mutant lung cancer. Group: Pharmaceutical. Alternative Names: CNX2006; CNX 2006; N-[3-[[2-[4-[[1-(2-fluoroethyl)azetidin-3-yl]amino]-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide. CAS No. 1375465-09-0. Pack Sizes: 10 mg. Product ID: B0084-462328. Molecular formula: C26H27F4N7O2. Mole weight: 545.543. Custom synthesis is available. Send your inquiries for more information. | London |
| EAI045 | EAI045 is an allosteric, non-ATP competitive inhibitor of mutant EGFR. In vitro studies proved that EAI045 is active and selective for T790M- harboring EGFR mutants that are in a monomer state. In vivo the combination of EAI045 and cetuximab caused a marked tumor shrinkage in a mouse model carrying the EGFR mutant with L858R/T790M/C797S. Therefore, EAI045 is the first allosteric inhibitor that targets T790M and C797S EGFR mutants but it is effective only in combination with cetuximab. Group: Pharmaceutical. Alternative Names: 2-(5-fluoro-2-hydroxyphenyl)-2-(3-oxo-1H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide; 2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide; EAI045; EAI 045; EAI-045. CAS No. 1942114-09-1. Pack Sizes: 50 mg. Product ID: B0084-475458. Molecular formula: C19H14FN3O3S. Mole weight: 383.397. Custom synthesis is available. Send your inquiries for more information. | London |
| EGF816 | EGF816, also called as Nazartinib, a covalent mutant-selective EGFR inhibitor and potently inhibits the T790M resistance mutation while sparing wild-type EGFR. in vivo: demonstrated strong tumor regressions in several EGFR activating and resistant tumor m. Group: Pharmaceutical. Alternative Names: EGF816; EGF-816; EGF 816; NVS-816; NVS 816; NVS816; Nazartinib; N-[7-chloro-1-[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]benzimidazol-2-yl]-2-methylpyridine-4-carboxamideEGF816UNII-KE7K32EME8KE7K32EME8EGF-8161508250-71-2GTPL9204SCHEMBL16767232SCHEMBL16767240EGF 816compound 47 [PMID: 27433829]. CAS No. 1508250-71-2. Pack Sizes: 10 mg. Product ID: B0084-474599. Molecular formula: C26H31ClN6O2. Mole weight: 495.02. Custom synthesis is available. Send your inquiries for more information. | London |
| Naquotinib | Naquotinib is an irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity with IC50 of 8-33 nM toward EGFR mutants. Group: Pharmaceutical. Alternative Names: ASP 8273; ASP8273; ASP-8273; (R)-5-((1-acryloylpyrrolidin-3-yl)oxy)-6-ethyl-3-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrazine-2-carboxamide. CAS No. 1448232-80-1. Pack Sizes: 5 mg. Product ID: B0084-475727. Molecular formula: C30H42N8O3. Mole weight: 562.719. Custom synthesis is available. Send your inquiries for more information. | London |
| Olmutinib | Olmutinib, also called as HM61713 and BI-1482694, is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed for treatment of advanced and metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC). In May 2016, olmutinib received its first global approval in South Korea for the treatment of EGFR T790M mutation-positive lung cancer. Olmutinib is also a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK). Group: Pharmaceutical. Alternative Names: N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; HM61713; HM 61713; HM-61713; BI 1482694; BI-1482694; BI1482694; Olmutinib. CAS No. 1353550-13-6. Pack Sizes: 200 mg. Product ID: B0084-470842. Molecular formula: C26H26N6O2S. Mole weight: 486.18. Custom synthesis is available. Send your inquiries for more information. | London |
| Rociletinib | Rociletinib is a third-generation irreversible kinase inhibitor of epidermal growth factor receptor (EGFR). Rociletinib was shown to inhibit the proliferation of non-small cell lung cancer (NSCLC) cells expressing mutant EGFR. It also exhibits anti-tumor activity in NSCLC EGFR mutant xenograft models. Group: Pharmaceutical. Alternative Names: CO-1686; CO1686; CO 1686; AVL-301; AVL 301; AVL301; CNX-419; CNX 419; CNX419; N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide. CAS No. 1374640-70-6. Pack Sizes: 100 mg. Product ID: B0084-462150. Molecular formula: C27H28F3N7O3. Mole weight: 555.562. Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
